公开(公告)号：US20150299330A1

公开(公告)日：2015-10-22

申请号：US14790144

申请日：2015-07-02

Applicant: JANSSEN BIOTECH, INC.

Inventor： John Chen ,  Johan Fransson ,  Natalie Fursov ,  Damon Hamel ,  Thomas Malia ,  Galina Obmolova ,  Tatiana Ort ,  Michael Rycyzyn ,  Michael Scully ,  Raymond Sweet ,  Alexey Teplyakov ,  John Wheeler ,  Juan Carlos Almagro

IPC: C07K16/28

CPC classification number: C07K16/2878 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Abstract translation: 对人CD27免疫特异性的人抗体能够阻断CD27与其配体CD70结合并中和CD27的生物活性，包括但不限于CD27细胞内信号传导，T细胞增殖和活化，B细胞增殖和分化，浆细胞形成和缓解 的抗体反应，通过CD70刺激肿瘤细胞，以及从T和B细胞产生可溶性介质。 该抗体可用于诊断或治疗CD27活动相关疾病和病症。

公开(公告)号：US20130243795A1

公开(公告)日：2013-09-19

申请号：US13835518

申请日：2013-03-15

Applicant: JANSSEN BIOTECH, INC.

Inventor： John Chen ,  Johan Fransson ,  Natalie Fursov ,  Damon Hamel ,  Thomas Malia ,  Galina Obmolova ,  Tatiana Ort ,  Michael Rycyzyn ,  Michael Scully ,  Raymond Sweet ,  Alexey Teplyakov ,  John Wheeler ,  Juan Carlos Almagro

IPC: C07K16/28

CPC classification number: C07K16/2878 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Abstract translation: 对人CD27免疫特异性的人抗体能够阻断CD27与其配体CD70结合并中和CD27的生物活性，包括但不限于CD27细胞内信号传导，T细胞增殖和活化，B细胞增殖和分化，浆细胞形成和缓解 的抗体反应，通过CD70刺激肿瘤细胞，以及从T和B细胞产生可溶性介质。 该抗体可用于诊断或治疗CD27活动相关疾病和病症。